305 related articles for article (PubMed ID: 10442045)
1. [Statistical evaluation of chronic granulomatous disease in Japan and basic studies for gene therapy for CGD patients].
Nunoi H; Ishibashi F
Rinsho Byori; 1999 Jul; 47(7):658-64. PubMed ID: 10442045
[TBL] [Abstract][Full Text] [Related]
2. [Gene therapy for inherited diseases using heamatopoietic stem cells--gene therapy for patients with chronic granulomatous disease].
Nunoi H; Ishibashi F
Hum Cell; 1999 Sep; 12(3):103-8. PubMed ID: 10695016
[TBL] [Abstract][Full Text] [Related]
3. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
4. A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox.
Leusen JH; de Boer M; Bolscher BG; Hilarius PM; Weening RS; Ochs HD; Roos D; Verhoeven AJ
J Clin Invest; 1994 May; 93(5):2120-6. PubMed ID: 8182143
[TBL] [Abstract][Full Text] [Related]
5. NADPH oxidase activity and cytochrome b558 content of human Epstein-Barr-virus-transformed B lymphocytes correlate with expression of genes encoding components of the oxidase system.
Condino-Neto A; Newburger PE
Arch Biochem Biophys; 1998 Dec; 360(2):158-64. PubMed ID: 9851826
[TBL] [Abstract][Full Text] [Related]
6. Genetic and biochemical background of chronic granulomatous disease.
Jurkowska M; Bernatowska E; Bal J
Arch Immunol Ther Exp (Warsz); 2004; 52(2):113-20. PubMed ID: 15179325
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of the autosomal recessive forms of chronic granulomatous disease.
Curnutte JT
Immunodefic Rev; 1992; 3(2):149-72. PubMed ID: 1554499
[TBL] [Abstract][Full Text] [Related]
8. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients.
Köker MY; Camcıoğlu Y; van Leeuwen K; Kılıç SŞ; Barlan I; Yılmaz M; Metin A; de Boer M; Avcılar H; Patıroğlu T; Yıldıran A; Yeğin O; Tezcan I; Sanal Ö; Roos D
J Allergy Clin Immunol; 2013 Nov; 132(5):1156-1163.e5. PubMed ID: 23910690
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of chronic granulomatous disease caused by defects in gp91-phox.
Patiño PJ; Perez JE; Lopez JA; Condino-Neto A; Grumach AS; Botero JH; Curnutte JT; García de Olarte D
Hum Mutat; 1999; 13(1):29-37. PubMed ID: 9888386
[TBL] [Abstract][Full Text] [Related]
10. [Molecular aspects of chronic granulomatous disease. "the NADPH oxidase complex"].
Morel F
Bull Acad Natl Med; 2007 Feb; 191(2):377-90; discussion 390-2. PubMed ID: 17969555
[TBL] [Abstract][Full Text] [Related]
11. Chronic granulomatous disease: towards gene therapy.
Thrasher A; Segal A; Casimir C
Immunodeficiency; 1993; 4(1-4):327-33. PubMed ID: 8167728
[TBL] [Abstract][Full Text] [Related]
12. Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients.
Wolach B; Gavrieli R; de Boer M; Gottesman G; Ben-Ari J; Rottem M; Schlesinger Y; Grisaru-Soen G; Etzioni A; Roos D
Clin Immunol; 2008 Oct; 129(1):103-14. PubMed ID: 18708296
[TBL] [Abstract][Full Text] [Related]
13. Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease.
Rappa G; Anzanello F; Alexeyev M; Fodstad O; Lorico A
Eur J Haematol; 2007 May; 78(5):440-8. PubMed ID: 17331133
[TBL] [Abstract][Full Text] [Related]
14. Three novel mutations in CYBA among 22 Iranians with Chronic granulomatous disease.
Badalzadeh M; Tajik S; Fazlollahi MR; Houshmand M; Fattahi F; Alizadeh Z; Movahedi M; Adab Z; Khotaei GT; Hamidieh AA; Heidarnazhad H; Pourpak Z
Int J Immunogenet; 2017 Dec; 44(6):314-321. PubMed ID: 28941186
[TBL] [Abstract][Full Text] [Related]
15. The expression of full length Gp91-phox protein is associated with reduced amphotropic retroviral production.
Bellantuono I; Lashford LS; Rafferty JA; Fairbairn LJ
Haematologica; 2000 May; 85(5):451-7. PubMed ID: 10800158
[TBL] [Abstract][Full Text] [Related]
16. Statistical and mutational analysis of chronic granulomatous disease in Japan with special reference to gp91-phox and p22-phox deficiency.
Ishibashi F; Nunoi H; Endo F; Matsuda I; Kanegasaki S
Hum Genet; 2000 May; 106(5):473-81. PubMed ID: 10914676
[TBL] [Abstract][Full Text] [Related]
17. Functional reconstitution of oxidase activity in X-linked chronic granulomatous disease by retrovirus-mediated gene transfer.
Zentilin L; Tafuro S; Grassi G; Garcia R; Ventura A; Baralle F; Falaschi A; Giacca M
Exp Cell Res; 1996 Jun; 225(2):257-67. PubMed ID: 8660913
[TBL] [Abstract][Full Text] [Related]
18. Homologous dinucleotide (GT or TG) deletion in Japanese patients with chronic granulomatous disease with p47-phox deficiency.
Iwata M; Nunoi H; Yamazaki H; Nakano T; Niwa H; Tsuruta S; Ohga S; Ohmi S; Kanegasaki S; Matsuda I
Biochem Biophys Res Commun; 1994 Mar; 199(3):1372-7. PubMed ID: 8147881
[TBL] [Abstract][Full Text] [Related]
19. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease.
Roesler J; Brenner S; Bukovsky AA; Whiting-Theobald N; Dull T; Kelly M; Civin CI; Malech HL
Blood; 2002 Dec; 100(13):4381-90. PubMed ID: 12393624
[TBL] [Abstract][Full Text] [Related]
20. Mutations of chronic granulomatous disease in Turkish families.
Köker MY; Sanal O; De Boer M; Tezcan I; Metin A; Ersoy F; Roos D
Eur J Clin Invest; 2007 Jul; 37(7):589-95. PubMed ID: 17576211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]